https://www.selleckchem.com/pr....oducts/gsk923295.htm
for patients with three or more comorbidities, p-value 0.001). Excluding anti-HCV therapies costs, HIV/HCV co-infected patients generally required more resources, with statistically significant differences related to cardiovascular events (€10,116.58 vs €11,004.28, p-value 0.001), and neurocognitive impairments events (€7706.43 vs €11,641.29 p- value 0.001). This study provides a differentiated and comprehensive analysis of the healthcare resources needed by HIV and HIV/HCV patients with comorbidities and may contribute to the de
Like
Comment
Share
